Milena Urbini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4006881/publications.pdf

Version: 2024-02-01

331259 395343 1,224 64 21 33 h-index citations g-index papers 65 65 65 1993 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. Cancers, 2022, 14, 1143.	1.7	23
2	Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. Cancers, 2022, 14, 2352.	1.7	2
3	Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. Journal of Clinical Medicine, 2021, 10, 1057.	1.0	9
4	Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling. Frontiers in Oncology, 2021, 11, 633543.	1.3	2
5	Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 5145.	1.8	2
6	Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications. Cancers, 2021, 13, 5223.	1.7	10
7	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2021, 11, 778461.	1.3	4
8	Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST. Scientific Reports, 2020, 10, 19829.	1.6	10
9	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers, 2020, 12, 2126.	1.7	44
10	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST. Frontiers in Oncology, 2020, 10, 504.	1.3	16
11	The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor. International Journal of Molecular Sciences, 2020, 21, 3313.	1.8	22
12	Genetic aberrations and molecular biology of cardiac sarcoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091849.	1.4	13
13	Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. Frontiers in Immunology, 2020, 11, 851.	2.2	10
14	Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?. Pharmacogenomics, 2020, 21, 231-234.	0.6	6
15	Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress. Frontiers in Oncology, 2020, 10, 564346.	1.3	7
16	Identification of SDHA germline mutations in sporadic SDHA mutant gastrointestinal stromal tumors (GIST): The need of a genetic counselling Journal of Clinical Oncology, 2020, 38, 11537-11537.	0.8	1
17	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. Oncolmmunology, 2019, 8, e1617588.	2.1	41
18	<p>Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets</p> . Cancer Management and Research, 2019, Volume 11, 6229-6244.	0.9	2

#	Article	IF	CITATIONS
19	The rs17084733 variant in the <i>KIT</i> 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. Epigenetics, 2019, 14, 545-557.	1.3	10
20	Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RASâ€P WT GIST. Genes Chromosomes and Cancer, 2019, 58, 636-642.	1.5	22
21	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib. Scientific Reports, 2019, 9, 2172.	1.6	5
22	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics Journal, 2019, 19, 390-400.	0.9	20
23	Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. World Journal of Clinical Cases, 2019, 7, 3018-3026.	0.3	7
24	Unusual bilateral ovarian metastases from ileal gastrointestinal stromal tumor (GIST): a case report. BMC Cancer, 2018, 18, 301.	1.1	6
25	Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. International Journal of Genomics, 2018, 2018, 1-9.	0.8	4
26	18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879356.	1.4	28
27	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. International Journal of Molecular Sciences, 2018, 19, 732.	1.8	29
28	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. International Journal of Molecular Sciences, 2018, 19, 1855.	1.8	4
29	Novel intraâ€genic large deletions of <i>CTNNB1</i> gene identified in WT desmoidâ€type fibromatosis. Genes Chromosomes and Cancer, 2018, 57, 495-503.	1.5	18
30	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2018, 36, 11534-11534.	0.8	1
31	Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC) Journal of Clinical Oncology, 2018, 36, 11561-11561.	0.8	0
32	Identification of an actionable mutation of <i>KIT</i> in extraskeletal myxoid chondrosarcoma (EMC) Journal of Clinical Oncology, 2018, 36, e23547-e23547.	0.8	0
33	Identification of novel intra-genic deletions of <i>CTNNB1</i> gene in WT desmoid-type fibromatosis Journal of Clinical Oncology, 2018, 36, 11577-11577.	0.8	0
34	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. Molecular Cancer Research, 2017, 15, 553-562.	1.5	53
35	Radiotherapy in the management of gist: state of the art and new potential scenarios. Clinical Sarcoma Research, 2017, 7, 1.	2.3	26
36	An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 2017, 20, 139-148.	3.7	10

#	Article	IF	CITATIONS
37	<scp>HSPA</scp> 8 as a novel fusion partner of <scp>NR</scp> 4 <scp>A</scp> 3 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes and Cancer, 2017, 56, 582-586.	1.5	38
38	The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). Journal of Translational Medicine, 2017, 15, 113.	1.8	43
39	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget, 2017, 8, 60036-60045.	0.8	17
40	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial–Mesenchymal Transition–like Process and 22q Loss. Molecular Cancer Research, 2016, 14, 820-829.	1.5	25
41	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Tumor Biology, 2016, 37, 13413-13423.	0.8	19
42	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 2016, 8, 1347-1366.	1.0	23
43	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clinical Cancer Research, 2016, 22, 837-846.	3.2	78
44	SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. BMC Medical Genetics, 2015, 16, 87.	2.1	22
45	Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney. Oncotarget, 2015, 6, 40934-40939.	0.8	61
46	Impact of Inflammatory Cytokine Gene Polymorphisms on Developing Acute Graft-versus-Host Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunology Research, 2015, 2015, 1-5.	0.9	5
47	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics, 2015, 16, 892.	1.2	48
48	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genetics in Medicine, 2015, 17, 391-395.	1.1	41
49	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget, 2015, 6, 42243-42257.	0.8	20
50	Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile Journal of Clinical Oncology, 2015, 33, 10553-10553.	0.8	1
51	Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14, 685.	1.1	70
52	Liquid biopsy in gastrointestinal stromal tumors: a novel approach. Journal of Translational Medicine, 2014, 12, 210.	1.8	17
53	Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. Clinical Sarcoma Research, 2014, 4, 9.	2.3	9
54	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. European Journal of Human Genetics, 2014, 22, 32-39.	1.4	90

#	Article	IF	CITATIONS
55	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. Oncotarget, 2014, 5, 108-119.	0.8	12
56	MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia. Oncotarget, 2014, 5, 120-130.	0.8	26
57	Integrate whole genomic study of KIT/PDGFRA wild-type (WT) GIST Journal of Clinical Oncology, 2014, 32, 10513-10513.	0.8	0
58	Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. Histology and Histopathology, 2014, 29, 167-75.	0.5	1
59	Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. Future Oncology, 2013, 9, 121-126.	1.1	30
60	Gene fusions evidence in a KIT/PDGFRA wild-type GIST without mutations in SDH units identified by a whole transcriptome study Journal of Clinical Oncology, 2013, 31, e21523-e21523.	0.8	0
61	Genome study of PDGFRA D842V mutant GIST using next generation sequencing approach Journal of Clinical Oncology, 2013, 31, 10540-10540.	0.8	O
62	Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours. Anti-Cancer Drugs, 2012, 23, 567-572.	0.7	16
63	SDHA and SDHB mutations in KIT/PDGFRA WT gastrointestinal stromal tumors Journal of Clinical Oncology, 2012, 30, 10087-10087.	0.8	1
64	A Distinct Pediatric-type Gastrointestinal Stromal Tumor in Adults. American Journal of Surgical Pathology, 2011, 35, 1750-1752.	2.1	40